CORALVILLE, IA – 11 October 2012 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has released the latest issue of DECODED. This quarter’s edition describes the research of Dr Vigneault (Church Laboratory, Harvard Medical School), and the lab’s use of IDT gBlocks™ Gene Fragments to study the biology of how patients respond to flu vaccines. Based on the immune response, the researchers employed gBlocks™ Gene Fragments to synthetically generate the variable regions of highly expressed antibody heavy chains. These were then re-introduced into the pool of light chain sequences to generate complete, single-chain variable fragments. Through subsequent analysis, this approach made it possible to identify the most effective antigen-binding sequences. Such findings could have substantial diagnostic and therapeutic potential. They are also a good example of how the ability to quickly and easily create custom gene segments is allowing researchers to unleash their experimental imaginations.
The complete article can be found in the October 2012 edition of DECODED. For more information on IDT products and services, please visit www.idtdna.com. For real-time news and updates, follow IDT on Twitter @idtdna or find us on Facebook.
About IDT
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT’s primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information visit www.idtdna.com.
Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
productinfo@idtdna.com
www.idtdna.com
